Scientists tout potential weight loss advance using gene technology
In findings published in the Proceedings of the National Academy of Sciences (PNAS) in the US, the team from the California-based Salk Institute for Biological Studies said that the microproteins "could potentially serve as drug targets to treat obesity and other metabolic disorders."
The findings could prove particularly useful for people who struggle with other treatments such as lifestyle changes, bariatric surgery or courses of drugs such as Ozempic and Wegovy.
"The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide," the Salk Institute warned, reminding that being overweight is linked to "other metabolic disorders" such as diabetes, cardiovascular diseases, chronic kidney disease, and cancers.
Microproteins, according to the team, are "an understudied class of molecules found throughout the body that play roles in both health and disease."
The team believes the findings are noteworthy because they entailed the use of CRISPR gene editing to screen thousands of fat cell genes to try to find genes "that likely code for microproteins that regulate either fat cell proliferation or lipid accumulation."
"We wanted to know if there was anything we had been missing in all these years of research into the body's metabolic processes," says Salk's Victor Pai.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Golden State Dermatology Grows to 10 Southern California Locations with Acquisition of Two-Location Practice
MONTCLAIR, Calif., Aug. 13, 2025 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with Dr. Laurie Woll's practice, with locations in Montclair and Glendora: 9301 Central Ave., Ste. 201, Montclair, CA and 210 S Grand Ave., Ste. 425, Glendora, CA. Dr. Laurie Woll, a board-certified dermatologist with over 45 years' experience, and her team of physician assistants provide a wide range of dermatology care. The team offers diagnosis and treatment for skin cancer, skin conditions, and more for all ages. They also provide popular cosmetic treatments, such as injectables and laser treatments, combining some of the latest in medical treatments and cosmetic enhancements with old-fashioned concern for their patients' well-being. They believe regular visits to a dermatologist are as important as the skin care regimen you follow at home. "I've always been dedicated to providing my patients with safe, advanced, and high-quality care. After careful consideration, I've decided to align with a group that shares my deep commitment to clinical excellence. I'm excited to start this new journey with GSD," said Dr. Woll. GSD has over 130 providers and 43 convenient locations throughout California, and accepts most forms of insurance. To learn more, visit Founder of GSD, Ed Becker, MD said, "Our focus is on empowering our clinicians so they can provide outstanding, patient-centered care in every community we serve. As we expand, we are dedicated to growing our network with care, partnering with top providers in California and across the country." About Golden State Dermatology Amid the health care consolidation, GSD was founded to maintain a relatively independent model of practice. GSD is physician-owned and led and is rapidly growing with a mission to deliver the highest quality care and a great patient, provider, and staff experience. GSD's services include dermatology, cosmetics, Mohs surgery, radiation therapy, pathology, and plastic surgery. GSD is actively looking to partner with leading dermatology clinics and dermatologists to further its vision to become the leading network of comprehensive dermatology services in the Western US. For more information about our partnership opportunities, visit View original content to download multimedia: SOURCE Golden State Dermatology
Geek Tyrant
2 hours ago
- Geek Tyrant
Two New STAR TREK Movies in the Works and The Franchise is a High Priority For Paramount Pictures — GeekTyrant
Paramount and Skydance Media are making Star Trek a major part of their post-merger film strategy. According to a new report from Deadline, the studio has two Star Trek movies currently in development, each taking the franchise in a different direction. One project is being directed by Toby Haynes ( Star Wars: Andor ) with a script from Seth Grahame-Smith. This film will introduce 'brand new characters,' offering a completely fresh crew and story. The other project is written by The Flight Attendant creator Steve Yockey and will center on the iconic team of Kirk, Spock, and the Enterprise. There are no release dates yet, and it's unclear which film will go into production first. The only certainty from the report is that Star Trek is now a 'high priority' for Paramount moving forward. The last Star Trek film to hit theaters was 2016's Star Trek Beyond , which was well-reviewed but underperformed financially, earning $343.3 million worldwide on a $185 million budget. Since then, multiple Star Trek movie concepts have been announced and scrapped, including Quentin Tarantino's standalone idea and Noah Hawley's version, which was abandoned partly because its plot involved a pandemic. Interestingly, Hawley's canceled film also planned to feature an all-new crew, which is an approach Haynes' project is now picking up. While nostalgia-driven sequels remain the industry's comfort zone, Star Trek has always thrived by creating new ensembles, from The Next Generation to Deep Space Nine . If the franchise wants to stay relevant for decades to come, introducing new characters is essential. That said, the appeal of another Kelvin Timeline film with Chris Pine, Zachary Quinto, and the rest of the cast is undeniable. Yockey's project could serve as a fitting send-off for this version of the Enterprise crew while Haynes' film sets the stage for a new era. If Paramount plays it right, fans might get both, a celebration of the past and a bold step into the future.
Yahoo
2 hours ago
- Yahoo
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2025, at 4:15 p.m. ET on Wednesday, August 13, 2025. Management will host a conference call on Wednesday, August 13, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through September 13, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 1454680. About the Hemopurifier® The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for: The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies. About Aethlon Medical, Inc. Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information, visit and follow the company on LinkedIn. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc.
